首页 > 最新文献

Klinicka Onkologie最新文献

英文 中文
Quantitative profiling of genes associated with cancer pathways in brain tumors. 脑肿瘤肿瘤通路相关基因的定量分析。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko2023224
Z Majerčíková, K Dibdiaková, M Galanda, T Galanda, R Richterová, B Kolarovszki, P Račay, J Hatok

Background: Brain tumors are a heterogeneous group of malignancies characterized by inter- and intratumoral heterogeneity. Among them, the most aggressive and, despite advances in medicine, still incurable remains glioblastoma. One of the reasons is the high recurrence rate of the disease and resistance to temozolomide, a golden standard in chemotherapy of brain tumors. Therefore, mapping the pathways responsible for tumorigenesis at the transcriptional level may help to determine the causes and aggressive behavior among different glial tumors.

Patients and methods: Biopsies from patients with astrocytoma (N = 6), glioblastoma (N = 22), and meningioma (N = 14) were included in the sample set. A control group consisted of RNA isolated from healthy human brain (N = 3). The reverse-transcribed cDNAs were analyzed using the Human Cancer PathwayFinder™ real-time PCR Array in a 96-well format. The expression of 84 genes belonging to 9 signaling pathways (angiogenesis, apoptosis, cell cycle and senescence, DNA damage and repair, epithelial-to-mesenchymal transition, hypoxia, overall metabolism, and telomere dynamics) was determined for each sample.

Results: By determining the relative expression of selected genes, we characterized the transcriptomic profile of individual brain malignancies in the context of signaling pathways involved in tumorigenesis. We observed deregulation in 50, 52.4 and 53.6% % of the genes in glioblastomas, meningiomas and astrocytomas, respectively. The most pronounced changes with statistical significance compared to control were observed in the genes associated with epithelial-to-mesenchymal transition (CDH2, FOXC2, GSC, SNAI2, and SOX10), cellular senescence (BMI1, ETS2, MAP2K1, and SOD1), DNA repair (DDB2, ERCC3, GADD45G, and LIG4), and dynamic of telomeres (TEP1, TERF2IP, TNKS, and TNKS2).

Conclusion: Based on the obtained data, we can conclude that individual diagnoses differ in transcriptomic profile. An individual molecular approach is therefore necessary in order to provide comprehensive and targeted therapy on multiple metabolic pathways in the diagnosis of brain tumors.

背景:脑肿瘤是一组异质性的恶性肿瘤,其特点是肿瘤间和肿瘤内的异质性。其中,最具侵略性的,尽管医学进步,仍然无法治愈的是胶质母细胞瘤。其中一个原因是该疾病的高复发率和对替莫唑胺的耐药性,替莫唑胺是脑肿瘤化疗的黄金标准。因此,在转录水平上绘制负责肿瘤发生的途径可能有助于确定不同胶质肿瘤的原因和侵袭性行为。患者和方法:从星形细胞瘤(N = 6)、胶质母细胞瘤(N = 22)和脑膜瘤(N = 14)患者中进行活检。对照组由从健康人脑中分离的RNA组成(N = 3)。使用human Cancer PathwayFinder™实时PCR阵列以96孔格式分析逆转录的cdna。每个样本的9条信号通路(血管生成、细胞凋亡、细胞周期和衰老、DNA损伤和修复、上皮-间质转化、缺氧、整体代谢和端粒动力学)中84个基因的表达均被检测。结果:通过确定选定基因的相对表达,我们在涉及肿瘤发生的信号通路的背景下表征了个体脑恶性肿瘤的转录组谱。我们在胶质母细胞瘤、脑膜瘤和星形细胞瘤中分别观察到50%、52.4和53.6%的基因缺失。与对照组相比,与上皮-间质转化相关的基因(CDH2、FOXC2、GSC、SNAI2和SOX10)、细胞衰老(BMI1、ETS2、MAP2K1和SOD1)、DNA修复(DDB2、ERCC3、GADD45G和LIG4)和端粒动态(TEP1、TERF2IP、TNKS和TNKS2)发生了最显著的变化,且具有统计学意义。结论:根据获得的数据,我们可以得出结论,个体诊断在转录组谱上存在差异。因此,为了在脑肿瘤诊断中提供多种代谢途径的综合和靶向治疗,个体分子方法是必要的。
{"title":"Quantitative profiling of genes associated with cancer pathways in brain tumors.","authors":"Z Majerčíková,&nbsp;K Dibdiaková,&nbsp;M Galanda,&nbsp;T Galanda,&nbsp;R Richterová,&nbsp;B Kolarovszki,&nbsp;P Račay,&nbsp;J Hatok","doi":"10.48095/ccko2023224","DOIUrl":"https://doi.org/10.48095/ccko2023224","url":null,"abstract":"<p><strong>Background: </strong>Brain tumors are a heterogeneous group of malignancies characterized by inter- and intratumoral heterogeneity. Among them, the most aggressive and, despite advances in medicine, still incurable remains glioblastoma. One of the reasons is the high recurrence rate of the disease and resistance to temozolomide, a golden standard in chemotherapy of brain tumors. Therefore, mapping the pathways responsible for tumorigenesis at the transcriptional level may help to determine the causes and aggressive behavior among different glial tumors.</p><p><strong>Patients and methods: </strong>Biopsies from patients with astrocytoma (N = 6), glioblastoma (N = 22), and meningioma (N = 14) were included in the sample set. A control group consisted of RNA isolated from healthy human brain (N = 3). The reverse-transcribed cDNAs were analyzed using the Human Cancer PathwayFinder™ real-time PCR Array in a 96-well format. The expression of 84 genes belonging to 9 signaling pathways (angiogenesis, apoptosis, cell cycle and senescence, DNA damage and repair, epithelial-to-mesenchymal transition, hypoxia, overall metabolism, and telomere dynamics) was determined for each sample.</p><p><strong>Results: </strong>By determining the relative expression of selected genes, we characterized the transcriptomic profile of individual brain malignancies in the context of signaling pathways involved in tumorigenesis. We observed deregulation in 50, 52.4 and 53.6% % of the genes in glioblastomas, meningiomas and astrocytomas, respectively. The most pronounced changes with statistical significance compared to control were observed in the genes associated with epithelial-to-mesenchymal transition (CDH2, FOXC2, GSC, SNAI2, and SOX10), cellular senescence (BMI1, ETS2, MAP2K1, and SOD1), DNA repair (DDB2, ERCC3, GADD45G, and LIG4), and dynamic of telomeres (TEP1, TERF2IP, TNKS, and TNKS2).</p><p><strong>Conclusion: </strong>Based on the obtained data, we can conclude that individual diagnoses differ in transcriptomic profile. An individual molecular approach is therefore necessary in order to provide comprehensive and targeted therapy on multiple metabolic pathways in the diagnosis of brain tumors.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"36 3","pages":"224-233"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9676586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of botulinum toxin in the management of radiotherapy side effects. 肉毒毒素在放射治疗副作用处理中的应用。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko2023348
Y B Cihan

Background: Many experimental and clinical studies are conducted to investigate the effects of various applications of botulinum toxin (BTx) in the treatment of radiation related side effects. There are no studies that show clear results about the positive and negative effects of its active clinical use in the long run, and discussions are ongoing. In addition, there is a need for various researches about how BTx can be used and how long it can be used, and the side effects it may cause. BTx-A, which is one of the options in the treatment of side effects that will occur due to radiotherapy, is an effective and safe option. Applying BTx injection to the right place with specific injection methods increases the effectiveness and safety of the treatment.

Purpose: It has been investigated whether BTx will be a potential tool to perfect the esthetic and functional results in reducing the chronic side effects associated with radiotherapy.

背景:进行了许多实验和临床研究,以研究肉毒杆菌毒素(BTx)在治疗辐射相关副作用中的各种应用效果。从长远来看,没有研究表明其积极临床应用的积极和消极影响有明确的结果,讨论正在进行中。此外,还需要对BTx的使用方法、使用时间以及可能引起的副作用进行各种研究。BTx-A是治疗放疗副作用的一种选择,是一种有效和安全的选择。采用特定的注射方法将BTx注射到正确的位置可以提高治疗的有效性和安全性。目的:已经研究了BTx是否会成为一种潜在的工具,以完善美学和功能结果,减少与放疗相关的慢性副作用。
{"title":"Use of botulinum toxin in the management of radiotherapy side effects.","authors":"Y B Cihan","doi":"10.48095/ccko2023348","DOIUrl":"10.48095/ccko2023348","url":null,"abstract":"<p><strong>Background: </strong>Many experimental and clinical studies are conducted to investigate the effects of various applications of botulinum toxin (BTx) in the treatment of radiation related side effects. There are no studies that show clear results about the positive and negative effects of its active clinical use in the long run, and discussions are ongoing. In addition, there is a need for various researches about how BTx can be used and how long it can be used, and the side effects it may cause. BTx-A, which is one of the options in the treatment of side effects that will occur due to radiotherapy, is an effective and safe option. Applying BTx injection to the right place with specific injection methods increases the effectiveness and safety of the treatment.</p><p><strong>Purpose: </strong>It has been investigated whether BTx will be a potential tool to perfect the esthetic and functional results in reducing the chronic side effects associated with radiotherapy.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"36 4","pages":"348-352"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50158947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of KDM1A and VEGF changes as the responsible genes in the angiogenesis of breast cancer. 研究乳腺癌血管生成的责任基因 KDM1A 和 VEGF 的变化。
Q4 Medicine Pub Date : 2023-01-01
N Hashemi, M Kavousi, F Jamshidian

Background: Recent developments regarding the contribution of microRNAs to tumor angiogenesis and the oncogenic effects of microRNAs point to their potential role in breast cancer angiogenesis. Tumor-derived exosomes are considered a rich source of microRNAs that can regulate the function of other cells in the tumor microenvironment, including vascular endothelial cells. This study analyzes the effect of tamoxifen chemotherapy on the expression of a key microRNA, miR-329, and introduces a regulatory link between this microRNA and the KDM1A gene associated with the vascular endothelial growth factor (VEGF) messaging pathway.

Materials and methods: MCF-7 breast cancer cells were purchased and cultured in a complete culture medium. These cells were treated with tamoxifen and then their exosomes were extracted from the culture medium. The RNAs of the exosomes were isolated and the expression of miR-329, VEGF, and KDM1A genes in the exosomes was investigated using the real-time polymerase chain reaction (PCR) method.

Results: The results of this study showed that tamoxifen treatment increased the expression of miR-329 in exosomes derived from MCF-7 cancer cells. The expression of KDM1A and VEGF genes in drug-treated cell exosomes is downregulated.

Conclusion: The results of this experiment demonstrated that the treatment of breast cancer cells with tamoxifen reduces the expression of VEGF and KDM1A by increasing miR-329. The treatment therefore reduces angiogenesis, and thus its anti-tumor effects are applied.

背景:有关微RNA对肿瘤血管生成的贡献以及微RNA致癌作用的最新进展表明,微RNA在乳腺癌血管生成中具有潜在作用。肿瘤衍生的外泌体被认为是微RNA的丰富来源,可调节肿瘤微环境中其他细胞(包括血管内皮细胞)的功能。本研究分析了他莫昔芬化疗对关键microRNA--miR-329表达的影响,并介绍了该microRNA与血管内皮生长因子(VEGF)信息传递途径相关的KDM1A基因之间的调控联系:购买 MCF-7 乳腺癌细胞并在完全培养基中培养。用他莫昔芬处理这些细胞,然后从培养基中提取它们的外泌体。分离外泌体的 RNA,采用实时聚合酶链反应(PCR)方法检测外泌体中 miR-329、VEGF 和 KDM1A 基因的表达:结果:研究结果表明,他莫昔芬治疗可增加MCF-7癌细胞外泌体中miR-329的表达。KDM1A和VEGF基因在药物处理的细胞外泌体中表达下调:本实验结果表明,用他莫昔芬治疗乳腺癌细胞可通过增加 miR-329 降低血管内皮生长因子和 KDM1A 的表达。因此,该疗法可减少血管生成,从而发挥其抗肿瘤作用。
{"title":"Study of KDM1A and VEGF changes as the responsible genes in the angiogenesis of breast cancer.","authors":"N Hashemi, M Kavousi, F Jamshidian","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Recent developments regarding the contribution of microRNAs to tumor angiogenesis and the oncogenic effects of microRNAs point to their potential role in breast cancer angiogenesis. Tumor-derived exosomes are considered a rich source of microRNAs that can regulate the function of other cells in the tumor microenvironment, including vascular endothelial cells. This study analyzes the effect of tamoxifen chemotherapy on the expression of a key microRNA, miR-329, and introduces a regulatory link between this microRNA and the KDM1A gene associated with the vascular endothelial growth factor (VEGF) messaging pathway.</p><p><strong>Materials and methods: </strong>MCF-7 breast cancer cells were purchased and cultured in a complete culture medium. These cells were treated with tamoxifen and then their exosomes were extracted from the culture medium. The RNAs of the exosomes were isolated and the expression of miR-329, VEGF, and KDM1A genes in the exosomes was investigated using the real-time polymerase chain reaction (PCR) method.</p><p><strong>Results: </strong>The results of this study showed that tamoxifen treatment increased the expression of miR-329 in exosomes derived from MCF-7 cancer cells. The expression of KDM1A and VEGF genes in drug-treated cell exosomes is downregulated.</p><p><strong>Conclusion: </strong>The results of this experiment demonstrated that the treatment of breast cancer cells with tamoxifen reduces the expression of VEGF and KDM1A by increasing miR-329. The treatment therefore reduces angiogenesis, and thus its anti-tumor effects are applied.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"37 4","pages":"281-286"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Building capacity for cancer care infrastructure in Karnataka - the present and the future. 卡纳塔克邦癌症护理基础设施的能力建设——现在和未来。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko202335
L Viswanath, S Palled, B Venugopal, C R Vijay, D Srinivasan, V D Nishchith

Background: Cancer mortality has doubled in India, a lower and middle-income country, from 1990 to 2016, depicting the ever-increasing burden of non-communicable disease. Karnataka, situated in the south of India, is one of the states with a rich medical college and hospital milieu. We present the status of cancer care across the state from the data collected by the investigators through public registries and personal communication to the concerned units to know the distribution of various services across the districts and give probable directives to improve on the present situation with emphasis on radiation therapy. This study may be taken as a bird's eye view of the situation across the country and form a basis based on which future planning of services and areas to emphasize on, may be considered.

Purpose: The establishment of a radiation therapy center holds the key to the establishment of comprehensive cancer care centers. The existing situation of such centers and the need and scope for inclusion and expansion of cancer units is presented in this article.

背景:从1990年到2016年,印度这个低收入和中等收入国家的癌症死亡率翻了一番,这表明非传染性疾病的负担不断增加。卡纳塔克邦位于印度南部,是拥有丰富医学院和医院环境的邦之一。我们从调查人员通过公共登记处和与有关单位的个人沟通收集的数据中展示了全州癌症治疗的现状,以了解各地区各种服务的分布情况,并给出可能的指示,以改善目前的状况,重点是放射治疗。这项研究可以作为全国情况的鸟瞰图,并在此基础上形成未来规划服务和重点领域的基础。目的:建立放射治疗中心是建立综合性癌症护理中心的关键。本文介绍了这些中心的现状以及纳入和扩大癌症单位的需要和范围。
{"title":"Building capacity for cancer care infrastructure in Karnataka - the present and the future.","authors":"L Viswanath,&nbsp;S Palled,&nbsp;B Venugopal,&nbsp;C R Vijay,&nbsp;D Srinivasan,&nbsp;V D Nishchith","doi":"10.48095/ccko202335","DOIUrl":"https://doi.org/10.48095/ccko202335","url":null,"abstract":"<p><strong>Background: </strong>Cancer mortality has doubled in India, a lower and middle-income country, from 1990 to 2016, depicting the ever-increasing burden of non-communicable disease. Karnataka, situated in the south of India, is one of the states with a rich medical college and hospital milieu. We present the status of cancer care across the state from the data collected by the investigators through public registries and personal communication to the concerned units to know the distribution of various services across the districts and give probable directives to improve on the present situation with emphasis on radiation therapy. This study may be taken as a bird's eye view of the situation across the country and form a basis based on which future planning of services and areas to emphasize on, may be considered.</p><p><strong>Purpose: </strong>The establishment of a radiation therapy center holds the key to the establishment of comprehensive cancer care centers. The existing situation of such centers and the need and scope for inclusion and expansion of cancer units is presented in this article.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"36 1","pages":"35-44"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9409728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osteoma of the ethmoid sinus in a pediatric patient - a case report. 小儿筛窦骨瘤1例报告。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko2023146
S Očkajová, G Bugová, A Hajtman

Background: Osteomas of the paranasal sinuses occur rarely in the pediatric population, we find only a few reference of symptomatic osteomas in the literature. Opinions on the indication for surgical treatment are controversial.

Case: The authors present a case of symptomatic osteoma of the right ethoimoidal sinus in a 12-year-old boy, who was treated surgically, with endoscopic endonasal approach. The symptomatology, diagnosis and therapy of these tumors in the pediatric patient are discussed.

Conclusion: Osteomas of the paranasal sinuses are slow-growing benign lesions. Symptomatic osteomas can grow expansively and cause serious complications. The treatment of osteoma is surgical and the endoscopic approach offers the possibility of removal with cosmetic benefits.

背景:鼻旁窦骨瘤在儿童人群中很少发生,我们在文献中只发现少数有症状的骨瘤。手术治疗的指征众说纷纭。病例:作者提出了一个12岁的男孩的症状性骨瘤的右蝶窦,谁是手术治疗,内镜鼻内入路。本文对小儿肿瘤的症状、诊断和治疗进行了讨论。结论:鼻窦骨瘤是一种生长缓慢的良性病变。有症状的骨瘤可大面积生长并引起严重的并发症。骨瘤的治疗是外科手术,内窥镜方法提供了切除的可能性和美容的好处。
{"title":"Osteoma of the ethmoid sinus in a pediatric patient - a case report.","authors":"S Očkajová,&nbsp;G Bugová,&nbsp;A Hajtman","doi":"10.48095/ccko2023146","DOIUrl":"https://doi.org/10.48095/ccko2023146","url":null,"abstract":"<p><strong>Background: </strong>Osteomas of the paranasal sinuses occur rarely in the pediatric population, we find only a few reference of symptomatic osteomas in the literature. Opinions on the indication for surgical treatment are controversial.</p><p><strong>Case: </strong>The authors present a case of symptomatic osteoma of the right ethoimoidal sinus in a 12-year-old boy, who was treated surgically, with endoscopic endonasal approach. The symptomatology, diagnosis and therapy of these tumors in the pediatric patient are discussed.</p><p><strong>Conclusion: </strong>Osteomas of the paranasal sinuses are slow-growing benign lesions. Symptomatic osteomas can grow expansively and cause serious complications. The treatment of osteoma is surgical and the endoscopic approach offers the possibility of removal with cosmetic benefits.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"36 2","pages":"146-149"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9788575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Neurobio-logy of multiple myeloma and its therapeutical use - results of the pilot study with a control arm. 多发性骨髓瘤的神经生物学及其治疗用途--带对照组的试点研究结果。
Q4 Medicine Pub Date : 2023-01-01
P Kotouček, R Enright, S Gregor Sorgerová, Ľ Hunáková, V Chlebcová, D Cholujová, J Jakubíková, B Mravec, E Naništová, Ľ Paneková, J Sedlák

Background: Myeloma cells, occupying a bone marrow niche, are influenced not only by neighbouring stroma cells but also by signals from the axons of sympathetic nervous system. The nervous system is directly involved in the process of myeloma progression. Among other cancers, patients with myeloma suffer the most difficult distress generating intensive adrenergic signals, causing its further progression. There is a question arising from these facts regarding whether psychological interventions, modulating a function of the nervous system, can further improve outcomes of myeloma treatments. We focus on interactions between myeloma cells and the nervous system.

Patients and methods: Twelve patients with monoclonal gamapathy of indetermined significance (MGUS) or myeloma have participated in this study; eight in the interventional arm with the intervention of forgiveness therapy and four in the control arm. The patients were in various phases of their treatment, from active observation to immuno-chemotherapy and autologous stem cell transplant. Two major types of parameters were measured during the intervention: parameters of the activity of the disease (MGUS or myeloma) and psycho-neuro-immunological parameters of the patient, such as psychological depression, anxiety, and anger by the validated test PROMIS), as well as activity of the autonomic nervous system by heart rate variability, and immune profile by flow cytometry of peripheral blood.

Results: Patients who completed the forgiveness intervention showed improvement of depression, anxiety, and anger measured by PROMIS above population average, significant expansion of physiological plasma cells CD138+38+ (P = 0.04), B memory lymphocytes CD27+ (P = 0.02), and dendritic plasmacytoid cells CD123+ (P = 0.03). Parameters of heart rate variability such as parasympatic nervous system (PNS) index, sympatic nervous system (SNS) index, stress index, standard deviation of NN intervals (SDNN) and root mean square of the successive differences (RMSSD) had improved in a majority of patients.

Conclusion: An intervention centered on forgiveness therapy was able to improve distress, reduce adrenergic signals in the autonomic nervous system, and restore parameters of the immune profile of patients with plasma cell dyscrasia who suffered from chronic stress caused by repressed anger and unforgiveness. Integrative treatment of myeloma can improve the quality of life of patients and thus affect the efficiency of immuno-chemotherapy. New randomised trials are warranted to test the integrative treatment of myeloma that might be able to improve overall survival.

背景:占据骨髓龛位的骨髓瘤细胞不仅受到邻近基质细胞的影响,还受到交感神经系统轴突信号的影响。神经系统直接参与骨髓瘤的发展过程。在其他癌症中,骨髓瘤患者最难以承受的痛苦是产生密集的肾上腺素能信号,导致病情进一步恶化。由此产生的一个问题是,通过调节神经系统的功能进行心理干预,能否进一步改善骨髓瘤的治疗效果。我们的研究重点是骨髓瘤细胞与神经系统之间的相互作用:12名意义未定的单克隆伽马病(MGUS)或骨髓瘤患者参加了这项研究;其中8人参加了宽恕疗法干预组,4人参加了对照组。这些患者处于不同的治疗阶段,从积极观察到免疫化疗和自体干细胞移植。在干预过程中测量了两类主要参数:疾病活动参数(MGUS或骨髓瘤)和患者的心理神经免疫参数,如心理抑郁、焦虑和愤怒(通过PROMIS有效测试),以及自律神经系统活动(通过心率变异性)和免疫概况(通过外周血流式细胞仪):结果:完成宽恕干预的患者通过 PROMIS 测定的抑郁、焦虑和愤怒程度的改善高于人群平均水平,生理性浆细胞 CD138+38+ (P = 0.04)、B 记忆淋巴细胞 CD27+ (P = 0.02)和树突状质细胞 CD123+ (P = 0.03)显著增加。大多数患者的心率变异性参数,如副交感神经系统(PNS)指数、交感神经系统(SNS)指数、压力指数、NNN间期标准偏差(SDNN)和连续差值均方根(RMSSD)均有所改善:结论:以宽恕疗法为核心的干预措施能够改善浆细胞瘤患者的痛苦,减少自律神经系统中的肾上腺素能信号,并恢复因压抑愤怒和不宽恕而长期承受压力的浆细胞瘤患者的免疫特征参数。骨髓瘤的综合治疗可以改善患者的生活质量,从而影响免疫化疗的效率。有必要进行新的随机试验,以检验骨髓瘤的综合治疗是否能提高总生存率。
{"title":"Neurobio-logy of multiple myeloma and its therapeutical use - results of the pilot study with a control arm.","authors":"P Kotouček, R Enright, S Gregor Sorgerová, Ľ Hunáková, V Chlebcová, D Cholujová, J Jakubíková, B Mravec, E Naništová, Ľ Paneková, J Sedlák","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Myeloma cells, occupying a bone marrow niche, are influenced not only by neighbouring stroma cells but also by signals from the axons of sympathetic nervous system. The nervous system is directly involved in the process of myeloma progression. Among other cancers, patients with myeloma suffer the most difficult distress generating intensive adrenergic signals, causing its further progression. There is a question arising from these facts regarding whether psychological interventions, modulating a function of the nervous system, can further improve outcomes of myeloma treatments. We focus on interactions between myeloma cells and the nervous system.</p><p><strong>Patients and methods: </strong>Twelve patients with monoclonal gamapathy of indetermined significance (MGUS) or myeloma have participated in this study; eight in the interventional arm with the intervention of forgiveness therapy and four in the control arm. The patients were in various phases of their treatment, from active observation to immuno-chemotherapy and autologous stem cell transplant. Two major types of parameters were measured during the intervention: parameters of the activity of the disease (MGUS or myeloma) and psycho-neuro-immunological parameters of the patient, such as psychological depression, anxiety, and anger by the validated test PROMIS), as well as activity of the autonomic nervous system by heart rate variability, and immune profile by flow cytometry of peripheral blood.</p><p><strong>Results: </strong>Patients who completed the forgiveness intervention showed improvement of depression, anxiety, and anger measured by PROMIS above population average, significant expansion of physiological plasma cells CD138+38+ (P = 0.04), B memory lymphocytes CD27+ (P = 0.02), and dendritic plasmacytoid cells CD123+ (P = 0.03). Parameters of heart rate variability such as parasympatic nervous system (PNS) index, sympatic nervous system (SNS) index, stress index, standard deviation of NN intervals (SDNN) and root mean square of the successive differences (RMSSD) had improved in a majority of patients.</p><p><strong>Conclusion: </strong>An intervention centered on forgiveness therapy was able to improve distress, reduce adrenergic signals in the autonomic nervous system, and restore parameters of the immune profile of patients with plasma cell dyscrasia who suffered from chronic stress caused by repressed anger and unforgiveness. Integrative treatment of myeloma can improve the quality of life of patients and thus affect the efficiency of immuno-chemotherapy. New randomised trials are warranted to test the integrative treatment of myeloma that might be able to improve overall survival.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"37 4","pages":"287-299"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A unique case of a giant ovarian mucinous cystadenoma causing an acute renal failure and compartment syndrome. 一个独特的情况下,巨大的卵巢粘液囊腺瘤引起急性肾功能衰竭和室室综合征。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko202365
V Bartoš, M Krištofík

Background: Mucinous cystadenoma of the ovary is a common gynecologic tumor that usually has a very favorable prognosis. However, if it is not early detected and removed, it can grow to a large size and may cause serious health complications.

Case: A 65-year-old woman was transported to the hospital by the emergency medical service due to overall weakness, markedly enlarged abdomen reminiscent of ascites, breathing difficulties, and swollen legs with eczematous ulcers. Laboratory parameters showed an acute renal insufficiency. Imaging scans revealed a giant solid cystic tumor mass filling the whole abdominopelvic cavity, which caused a compartment syndrome of the lower limbs. After relieving puncture and drainage of 6 L of fluid from the cyst, laparotomy had been performed. Grossly, the entire abdominal cavity was filled with a huge cystic tumor originating from the left ovary. During its surgical preparation, a total of 17 L of fluid was evacuated from it. Then, adnexectomy was made. A bio-psy sample consisted of an irregular, artificially teared multicystic tumor about 60 cm in the largest dimension. Histology confirmed a benign mucinous cystadenoma. After tumor removal, the patient's health condition and laboratory parameters improved.

Conclusion: We described a unique case of an extremely huge ovarian mucinous cystadenoma that led to a life-threating event of the patient. We tried to point out that even a "common" benign tumor may lead to clinically malignant consequences and its management requires a multidisciplinary approach.

背景:卵巢粘液囊腺瘤是一种常见的妇科肿瘤,通常预后良好。然而,如果不及早发现并切除,它可能会长得很大,并可能导致严重的健康并发症。病例:一名65岁女性,因全身虚弱、腹部明显增大,令人想起腹水、呼吸困难和腿部肿胀伴湿疹性溃疡被紧急医疗服务送往医院。实验室参数显示急性肾功能不全。成像扫描显示一个巨大的实性囊性肿瘤肿块充满整个腹腔,引起下肢隔室综合征。在解除穿刺并从囊肿中抽出6升液体后,进行剖腹手术。肉眼可见,整个腹腔充满了源自左侧卵巢的巨大囊性肿瘤。在手术准备过程中,共排出17 L液体。然后行附件切除术。活检样本包括一个不规则的,人工撕裂的多囊肿瘤,最大尺寸约60厘米。组织学证实为良性粘液囊腺瘤。肿瘤切除后,患者的健康状况和实验室参数得到改善。结论:我们描述了一个独特的情况下,一个巨大的卵巢粘液囊腺瘤,导致患者的生命危险事件。我们试图指出,即使是一个“常见的”良性肿瘤也可能导致临床恶性后果,其治疗需要多学科的方法。
{"title":"A unique case of a giant ovarian mucinous cystadenoma causing an acute renal failure and compartment syndrome.","authors":"V Bartoš,&nbsp;M Krištofík","doi":"10.48095/ccko202365","DOIUrl":"https://doi.org/10.48095/ccko202365","url":null,"abstract":"<p><strong>Background: </strong>Mucinous cystadenoma of the ovary is a common gynecologic tumor that usually has a very favorable prognosis. However, if it is not early detected and removed, it can grow to a large size and may cause serious health complications.</p><p><strong>Case: </strong>A 65-year-old woman was transported to the hospital by the emergency medical service due to overall weakness, markedly enlarged abdomen reminiscent of ascites, breathing difficulties, and swollen legs with eczematous ulcers. Laboratory parameters showed an acute renal insufficiency. Imaging scans revealed a giant solid cystic tumor mass filling the whole abdominopelvic cavity, which caused a compartment syndrome of the lower limbs. After relieving puncture and drainage of 6 L of fluid from the cyst, laparotomy had been performed. Grossly, the entire abdominal cavity was filled with a huge cystic tumor originating from the left ovary. During its surgical preparation, a total of 17 L of fluid was evacuated from it. Then, adnexectomy was made. A bio-psy sample consisted of an irregular, artificially teared multicystic tumor about 60 cm in the largest dimension. Histology confirmed a benign mucinous cystadenoma. After tumor removal, the patient's health condition and laboratory parameters improved.</p><p><strong>Conclusion: </strong>We described a unique case of an extremely huge ovarian mucinous cystadenoma that led to a life-threating event of the patient. We tried to point out that even a \"common\" benign tumor may lead to clinically malignant consequences and its management requires a multidisciplinary approach.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"36 1","pages":"65-70"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9393223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Image guided adaptive brachytherapy of cervical cancer - practical recommendations. 影像引导下宫颈癌适应性近距离放射治疗的实用建议。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko202396
R Vojtíšek

Brachytherapy (BT) is an integral part of radical radiotherapy (RT) or radiochemotherapy (RCT) in patients who are not suitable candidates for surgery. These are usually patients with locally advanced cervical cancer. The goal of all BT planning eff orts has been, still is, and certainly will continue to be, to defi ne the anatomical boundaries of the tumor and the relationship of the tumor to organs at risk (OARs) as best as possible, using available modern imaging techniques. Image guided adaptive brachytherapy (IGABT) is currently the most advanced method of uterovaginal BT. Adaptive planning allows dose escalation from BT to newly defi ned target volumes, according to the risk of recurrence, which is mainly determined by the level of tumor burden. This dose adaptation based on the response to external RCT is a major change in practice compared to conventional BT planning based on dose prescription to point A. The main advantage of the IGABT concept is that it allows the assessment of individual dose distributions in target volumes and OARs, which in turn leads to improved dose coverage of target volumes while decreasing the volume irradiated by the prescribed dose compared to conventional 2D planning. Purpose: In this review article, I provide a comprehensive up-to-date perspective on this issue, particularly in terms of practical recommendations regarding the defi nition of target volumes, the use of diff erent types of uterovaginal applicators, intraoperative complications, and potential manifestations of late gastrointestinal, genitourinary, and vaginal toxicity.

对于不适合手术的患者,近距离放疗(BT)是根治性放疗(RT)或放化疗(RCT)的重要组成部分。这些患者通常是局部晚期宫颈癌患者。所有BT计划工作的目标一直是,现在仍然是,并且肯定会继续是,利用现有的现代成像技术,尽可能地确定肿瘤的解剖边界和肿瘤与危险器官(OARs)的关系。图像引导适应性近距离放射治疗(IGABT)是目前最先进的子宫阴道BT治疗方法,适应性规划允许根据复发风险(主要由肿瘤负荷水平决定)从BT剂量递增到新定义的目标体积。与基于a点剂量处方的传统BT计划相比,这种基于外部RCT反应的剂量调整在实践中是一个重大变化。IGABT概念的主要优势在于,它允许评估靶体积和桨叶中的个体剂量分布,这反过来又导致靶体积的剂量覆盖得到改善,同时与传统的二维计划相比,规定剂量照射的体积减小。目的:在这篇综述文章中,我就这一问题提供了一个全面的最新观点,特别是关于靶体积的定义、不同类型子宫阴道涂布器的使用、术中并发症以及晚期胃肠道、泌尿生殖系统和阴道毒性的潜在表现方面的实用建议。
{"title":"Image guided adaptive brachytherapy of cervical cancer - practical recommendations.","authors":"R Vojtíšek","doi":"10.48095/ccko202396","DOIUrl":"https://doi.org/10.48095/ccko202396","url":null,"abstract":"<p><p>Brachytherapy (BT) is an integral part of radical radiotherapy (RT) or radiochemotherapy (RCT) in patients who are not suitable candidates for surgery. These are usually patients with locally advanced cervical cancer. The goal of all BT planning eff orts has been, still is, and certainly will continue to be, to defi ne the anatomical boundaries of the tumor and the relationship of the tumor to organs at risk (OARs) as best as possible, using available modern imaging techniques. Image guided adaptive brachytherapy (IGABT) is currently the most advanced method of uterovaginal BT. Adaptive planning allows dose escalation from BT to newly defi ned target volumes, according to the risk of recurrence, which is mainly determined by the level of tumor burden. This dose adaptation based on the response to external RCT is a major change in practice compared to conventional BT planning based on dose prescription to point A. The main advantage of the IGABT concept is that it allows the assessment of individual dose distributions in target volumes and OARs, which in turn leads to improved dose coverage of target volumes while decreasing the volume irradiated by the prescribed dose compared to conventional 2D planning. Purpose: In this review article, I provide a comprehensive up-to-date perspective on this issue, particularly in terms of practical recommendations regarding the defi nition of target volumes, the use of diff erent types of uterovaginal applicators, intraoperative complications, and potential manifestations of late gastrointestinal, genitourinary, and vaginal toxicity.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"36 2","pages":"96-103"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9419857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A rare case of urothelial carcinoma metastasizing to the gallbladder wall with manifestations as acute cholecystitis. 摘要罕见的尿路上皮癌转移至胆囊壁,表现为急性胆囊炎。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko2023401
A Berková, Z Chovanec, I Krejčová, J Katolická, Z Bednařík, V Červeňák, P Vlček, I Penka

Background: Metastasis to the gallbladder is very rare. This case report highlights a rare cause of acute cholecystitis, which should be considered by the surgeon and other treating physicians in the differential diagnosis of patients with urothelial carcinoma.

Case: We report the case of a 73 year-old man with follow-up oncology care. He was diagnosed with infiltrating urothelial carcinoma in 2019, received neoadjuvant chemotherapy, and subsequently underwent radical cystectomy with ureteroileostomy in April 2020. Histology confirmed complete regression of bladder cancer, the lymphonodes were also free of tumour infiltration. In July 2021, the patient was examined for intermittent abdominal pain, predominantly of the right upper quadrant. On clinical examination, the gallbladder hydrops was palpable and a positive Murphy's sign was present. Due to the signs of acute cholecystitis, the patient was indicated for acute cholecystectomy. Gallbladder histology revealed metastatic involvement of the gallbladder wall by urothelial carcinoma.

Conclusion: If patients with bladder cancer present with intermittent right subcostal pain or signs of acute cholecystitis and diagnostic imaging shows a thickened gallbladder wall, clinicians and radiologists should consider the possibility of metastatic origin of lesion.

背景:胆囊转移是非常罕见的。本病例报告强调了急性胆囊炎的一种罕见原因,外科医生和其他治疗医生在鉴别诊断尿路上皮癌患者时应考虑这一点。病例:我们报告一位73岁男性的病例,接受后续肿瘤治疗。他于2019年被诊断为浸润性尿路上皮癌,接受了新辅助化疗,随后于2020年4月接受了输尿管回肠造口术根治性膀胱切除术。组织学证实癌症完全消退,淋巴结也没有肿瘤浸润。2021年7月,患者接受了间歇性腹痛检查,主要是右上象限。在临床检查中,胆囊积水是可触摸的,并出现阳性墨菲征。由于急性胆囊炎的症状,该患者被要求进行急性胆囊切除术。胆囊组织学显示尿路上皮癌转移到胆囊壁。结论:如果癌症患者出现间歇性右肋下疼痛或急性胆囊炎体征,且诊断性影像学显示胆囊壁增厚,临床医生和放射科医生应考虑病灶转移来源的可能性。
{"title":"A rare case of urothelial carcinoma metastasizing to the gallbladder wall with manifestations as acute cholecystitis.","authors":"A Berková,&nbsp;Z Chovanec,&nbsp;I Krejčová,&nbsp;J Katolická,&nbsp;Z Bednařík,&nbsp;V Červeňák,&nbsp;P Vlček,&nbsp;I Penka","doi":"10.48095/ccko2023401","DOIUrl":"10.48095/ccko2023401","url":null,"abstract":"<p><strong>Background: </strong>Metastasis to the gallbladder is very rare. This case report highlights a rare cause of acute cholecystitis, which should be considered by the surgeon and other treating physicians in the differential diagnosis of patients with urothelial carcinoma.</p><p><strong>Case: </strong>We report the case of a 73 year-old man with follow-up oncology care. He was diagnosed with infiltrating urothelial carcinoma in 2019, received neoadjuvant chemotherapy, and subsequently underwent radical cystectomy with ureteroileostomy in April 2020. Histology confirmed complete regression of bladder cancer, the lymphonodes were also free of tumour infiltration. In July 2021, the patient was examined for intermittent abdominal pain, predominantly of the right upper quadrant. On clinical examination, the gallbladder hydrops was palpable and a positive Murphy's sign was present. Due to the signs of acute cholecystitis, the patient was indicated for acute cholecystectomy. Gallbladder histology revealed metastatic involvement of the gallbladder wall by urothelial carcinoma.</p><p><strong>Conclusion: </strong>If patients with bladder cancer present with intermittent right subcostal pain or signs of acute cholecystitis and diagnostic imaging shows a thickened gallbladder wall, clinicians and radiologists should consider the possibility of metastatic origin of lesion.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"36 4","pages":"401-404"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50158940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stereotactic body radiation therapy in the treatment of early-stage non-small cell lung cancer. 立体定向体放射治疗早期非小细胞肺癌。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko2023370
K Resová, T Paračková, J Cvek

Background: Stereotactic body radiation therapy (SBRT) is now a standard treatment option for patients with early-stage non-small cell lung cancer (ES-NSCLC) who are unfit for surgery or refuse to undergo an operation. SBRT is a method of external beam radiotherapy that accurately delivers a high dose of irradiation in one or few treatment fractions. Intensive regimens of biologically effective dose ≥ 100 Gy are associated with good local control and overall survival, higher than in conventionally fractionated radiotherapy. There are still controversial areas in the SBRT indication where data are limited - indications for elderly and comorbid patients, indications for treatment without histological verification, treatment of central/ultracentral lesions, indications for tumors larger than 5 cm, indications for operable patients. The optimal follow-up practice of these patients also remains unclear, including the frequency of imaging, the use of PET-CT, and requirements for biopsy. CT changes after SBRT differ from those following conventional radiotherapy and it is difficult to distinguish them from tumor recurrence. Due to the high local control achieved with lung SBRT, data on the treatment of local failure are insufficient.

Purpose: The aim of the publication is to demonstrate the current information and the importance of SBRT for patients with ES-NSCLC.

背景:立体定向身体放射治疗(SBRT)目前是不适合手术或拒绝手术的早期癌症(ES-NSCLC)患者的标准治疗选择。SBRT是一种外束放射治疗方法,可以在一个或几个治疗部分中准确地提供高剂量的照射。生物学有效剂量≥100 Gy的强化方案与良好的局部控制和总生存率相关,高于常规分割放疗。SBRT适应症仍有争议,数据有限——老年和合并症患者的适应症、未经组织学验证的治疗适应症、中心/超中心病变的治疗、大于5的肿瘤的适应症 cm,可手术患者的适应症。这些患者的最佳随访实践也不清楚,包括成像频率、PET-CT的使用和活检要求。SBRT后的CT变化与常规放疗后的不同,很难将其与肿瘤复发区分开来。由于肺SBRT实现了高度的局部控制,关于局部衰竭治疗的数据不足。目的:该出版物的目的是证明SBRT对ES-NSCLC患者的当前信息和重要性。
{"title":"Stereotactic body radiation therapy in the treatment of early-stage non-small cell lung cancer.","authors":"K Resová,&nbsp;T Paračková,&nbsp;J Cvek","doi":"10.48095/ccko2023370","DOIUrl":"10.48095/ccko2023370","url":null,"abstract":"<p><strong>Background: </strong>Stereotactic body radiation therapy (SBRT) is now a standard treatment option for patients with early-stage non-small cell lung cancer (ES-NSCLC) who are unfit for surgery or refuse to undergo an operation. SBRT is a method of external beam radiotherapy that accurately delivers a high dose of irradiation in one or few treatment fractions. Intensive regimens of biologically effective dose ≥ 100 Gy are associated with good local control and overall survival, higher than in conventionally fractionated radiotherapy. There are still controversial areas in the SBRT indication where data are limited - indications for elderly and comorbid patients, indications for treatment without histological verification, treatment of central/ultracentral lesions, indications for tumors larger than 5 cm, indications for operable patients. The optimal follow-up practice of these patients also remains unclear, including the frequency of imaging, the use of PET-CT, and requirements for biopsy. CT changes after SBRT differ from those following conventional radiotherapy and it is difficult to distinguish them from tumor recurrence. Due to the high local control achieved with lung SBRT, data on the treatment of local failure are insufficient.</p><p><strong>Purpose: </strong>The aim of the publication is to demonstrate the current information and the importance of SBRT for patients with ES-NSCLC.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"36 4","pages":"370-377"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50158944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Klinicka Onkologie
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1